GoAI
Get started
BioAtla, Inc. logo

BioAtla, Inc.

BCAB

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$3.56

+$0.38 · +11.95%

Aug 24, 10:55 AM ET

BCAB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

25

Weakening

Sentiment

33

Bearish

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jay Short
Listed since
Dec 16, 2020
Employees
41

Market position

Day range

Current $3.56

52-week range

Current $3.56

Open
$3.27
Previous close
$3.18
Volume
176.45K
3.4× average
Average volume
51.91K
Average daily volume
Market cap
6.56M USD
Beta
0.76
Market reference 1
50-day average
$3.6005
-1.12% below average
200-day average
$13.5413
-73.71% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
32.48M USD
P/E (TTM)
-0.16×
P/B (TTM)
-0.18×
P/S (TTM)
0.77×
EV / EBITDA
-0.55×
Earnings yield
-178.45%
Free cash flow yield
-144.31%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-4.15%
Operating margin
-372.06%
Net margin
-370.05%
Return on equity
164.71%
Return on assets
-431.06%
Return on invested capital
889.53%

Financial health

Debt / equity
-0.16×
Current ratio
0.37×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3958%-11509%-26976%-42443%Gross margin, FY2021: -23209.60%Gross margin, FY2024: 91.59%Gross margin, FY2025: -2053.65%Operating margin, FY2021: -38576.00%Operating margin, FY2024: -672.21%Operating margin, FY2025: -2965.25%Net margin, FY2021: -38160.80%Net margin, FY2024: -634.33%Net margin, FY2025: -2980.35%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -23209.60%. Gross margin FY2024 91.59%. Gross margin FY2025 -2053.65%. Operating margin FY2021 -38576.00%. Operating margin FY2024 -672.21%. Operating margin FY2025 -2965.25%. Net margin FY2021 -38160.80%. Net margin FY2024 -634.33%. Net margin FY2025 -2980.35%.

Income trends

Revenue

2M USD-81.82%

Operating income

−59.31M USD+19.80%

Net income

−59.61M USD+14.57%
Income trends across reported periods25.07M USD−31.21M USD−87.48M USD−143.76M USDRevenue, FY2021: 250K USDRevenue, FY2024: 11M USDRevenue, FY2025: 2M USDOperating income, FY2021: −96.44M USDOperating income, FY2022: −108.14M USDOperating income, FY2023: −129.69M USDOperating income, FY2024: −73.94M USDOperating income, FY2025: −59.31M USDNet income, FY2021: −95.4M USDNet income, FY2022: −105.28M USDNet income, FY2023: −123.46M USDNet income, FY2024: −69.78M USDNet income, FY2025: −59.61M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 250K USD. Revenue FY2024 11M USD. Revenue FY2025 2M USD. Operating income FY2021 −96.44M USD. Operating income FY2022 −108.14M USD. Operating income FY2023 −129.69M USD. Operating income FY2024 −73.94M USD. Operating income FY2025 −59.31M USD. Net income FY2021 −95.4M USD. Net income FY2022 −105.28M USD. Net income FY2023 −123.46M USD. Net income FY2024 −69.78M USD. Net income FY2025 −59.61M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2M USD11M USD——250K USD
Cost of goods sold43.07M USD925K USD1.22M USD1.2M USD58.27M USD
Gross profit−41.07M USD10.08M USD−1.22M USD−1.2M USD−58.02M USD
Research and development43.57M USD63.1M USD103.73M USD79.35M USD58.27M USD
Selling, general, and administrative17.63M USD21.85M USD25.96M USD28.79M USD38.42M USD
Operating expenses18.23M USD84.02M USD128.47M USD106.94M USD38.42M USD
Interest income843K USD3.37M USD6.31M USD1.65M USD350K USD
Interest expense————3K USD
Depreciation and amortization373K USD925K USD1.22M USD1.2M USD1.33M USD
Operating income−59.31M USD−73.94M USD−129.69M USD−108.14M USD−96.44M USD
Net income−59.61M USD−69.78M USD−123.46M USD−105.28M USD−95.4M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-2867.58%
11 comparable reports
Latest EPS result
0.27
Estimate -8.5 · Beat by 103.18%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.57-4.72-11.01-17.3Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -15, estimate -0.4, surprise -3650.00%, Miss. Q2 2025, reported May 6, 2025: actual -13, estimate -0.293, surprise -4331.87%, Miss. Q3 2025, reported Aug 7, 2025: actual -16, estimate -0.293, surprise -5354.61%, Miss. Q4 2025, reported Nov 13, 2025: actual -13.5, estimate -0.31, surprise -4254.84%, Miss. Q1 2026, reported Mar 31, 2026: actual -8, estimate -12, surprise +33.33%, Beat. Q2 2026, reported May 15, 2026: actual -6.18, estimate -10, surprise +38.20%, Beat. Q3 2026, reported Aug 13, 2026: actual 0.27, estimate -8.5, surprise +103.18%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -7, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates16.14M10.96M5.78M595KQ1 '24EstimateQ4 '24No estimateQ1 '26BeatQ3 '26MetQ4 '26Estimate
Q1 2024, reported Mar 26, 2024: actual —, estimate 15M USD, surprise —, Comparison unavailable. Q4 2024, reported Nov 7, 2024: actual 11M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual 2M USD, estimate 700K USD, surprise +185.71%, Beat. Q3 2026, reported Aug 13, 2026: actual 6.5M USD, estimate 6.5M USD, surprise 0.00%, Met estimate. Q4 2026, reported Nov 12, 2026: actual —, estimate 5.59M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

4 institutions
Citizens Capital MarketsmaintainMarket Outperform
JP MorganmaintainOverweight

BCAB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

Continue in GoAI

Research BCAB

research.disclaimer